TipRanks
pc:nan6z

NanoPhoria Bioscience

NanoPhoria Bioscience is a Milan-based biotech company specializing in the development of a nano-in-micro and lung-to-heart delivery platform utilizing inorganic calcium phosphate nanoparticles. The company's lead product, NP-MP1, is a first-in-class peptide designed to target cardiac L-type calcium channels, aiming to improve ejection fraction in patients with heart failure with reduced ejection fraction (HFrEF). NanoPhoria's innovative platform seeks to address unmet medical needs by enhancing cardiac contractility and offering new treatment paradigms for cardiovascular and other chronic diseases.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$84M
Total Amount Raised$84M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$84M
Latest Funding Amount$84M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Series A
$83.50M
―

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to NanoPhoria Bioscience, helping you discover and navigate related company profiles.

Related News and Analysis